Form 4: Illumina VP, Chief Accounting Officer, Scott D. Ericksen, Reports Acquisition of Restricted Stock Units and Performance Shares

Scott D. Ericksen, VP, Chief Accounting Officer of Illumina, Inc., reports the acquisition of restricted stock units and performance shares on March 5, 2024.

Summary

• On March 5, 2024, Scott D. Ericksen, VP, Chief Accounting Officer of Illumina, Inc., acquired 2,971 shares of common stock.
• These shares were granted as restricted stock units.
• Ericksen also acquired 1,486 performance shares linked to the company's three-year average operating margin for fiscal years 2024-2026, vesting on January 3, 2027.
• An additional 1,486 performance shares were acquired, tied to the company's relative total shareholder return for the fiscal year ending January 3, 2027.
• The number of shares issued for both performance stock unit grants will range from 0% to 200% of the amount specified, based on the company's performance relative to pre-defined objectives, subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, aligning management interests with company performance, which is generally viewed positively.

Positives

• The grant of restricted stock units and performance shares aligns the executive's interests with the long-term performance of the company.
• The performance shares are tied to key metrics such as operating margin and total shareholder return, incentivizing value creation.

Risks

• The actual number of performance shares that will vest is contingent on the company's performance against pre-defined objectives, introducing uncertainty.

Future Outlook

The vesting of the performance shares is contingent on the company's future performance related to operating margin and total shareholder return.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain talent and align executive interests with shareholder value.

Comparison to Industry Standards

• Companies like Thermo Fisher Scientific and Danaher also utilize performance-based equity compensation to incentivize executives.
• The specific metrics used (operating margin, total shareholder return) are common benchmarks for assessing company performance in the industry.
• The vesting schedules are fairly standard, with multi-year vesting periods to encourage long-term commitment.

Stakeholder Impact

• Shareholders: The equity grants align executive compensation with company performance, potentially benefiting shareholders.
• Employees: The grants may serve as a motivating factor for other employees, as they demonstrate the company's commitment to rewarding performance.

Key Dates